C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
4.480
+0.110 (2.52%)
Jun 1, 2026, 10:48 AM EDT - Market open
C4 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 35.64 | 35.95 | 35.58 | 31.1 | 45.79 | 33.2 | |
Revenue Growth (YoY) | 0.15% | 1.02% | 14.43% | -32.08% | 37.93% | 55.25% |
Gross Profit | 35.64 | 35.95 | 35.58 | 31.1 | 45.79 | 33.2 |
Selling, General & Admin | 36.76 | 36.2 | 42.12 | 42.79 | 33.25 | 15.2 |
Research & Development | 102.65 | 104.24 | 110.64 | 117.84 | 94.67 | 78.44 |
Other Operating Expenses | 10.73 | 10.73 | 2.44 | - | - | - |
Total Operating Expenses | 150.14 | 151.17 | 155.2 | 160.63 | 127.92 | 93.64 |
Operating Income | -114.51 | -115.22 | -119.61 | -129.53 | -82.13 | -60.45 |
Interest Income | 10.52 | 10.35 | 14.43 | 3.58 | 0.39 | 0.39 |
Interest Expense | - | - | - | -2.22 | -2.15 | -1.23 |
Other Non-Operating Income (Expense) | - | - | - | - | - | -5.68 |
Total Non-Operating Income (Expense) | 10.52 | 10.35 | 14.43 | 1.36 | -1.76 | -6.51 |
Pretax Income | -52.53 | -104.87 | -105.19 | -128.18 | -83.89 | -66.96 |
Provision for Income Taxes | - | - | - | - | - | -0.63 |
Net Income | -104.1 | -104.99 | -105.32 | -128.18 | -83.89 | -66.34 |
Net Income to Common | -104.1 | -104.99 | -105.32 | -128.18 | -83.89 | -66.34 |
Shares Outstanding (Basic) | 97 | 83 | 69 | 49 | 46 | 11 |
Shares Outstanding (Diluted) | 97 | 83 | 69 | 49 | 46 | 11 |
Shares Change (YoY) | 39.20% | 19.49% | 41.98% | 6.13% | 304.93% | 728.79% |
EPS (Basic) | -1.19 | -1.27 | -1.52 | -2.62 | -1.82 | -5.83 |
EPS (Diluted) | -1.19 | -1.27 | -1.52 | -2.62 | -1.82 | -5.83 |
Shares Outstanding | 104.04 | 96.91 | 70.63 | - | - | - |
Free Cash Flow | - | -99.3 | -65.34 | -111.44 | -88.24 | -67.9 |
Free Cash Flow Per Share | - | -1.20 | -0.94 | -2.28 | -1.92 | -5.97 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -321.32% | -320.53% | -336.14% | -416.56% | -179.39% | -182.10% |
Profit Margin | -147.41% | -291.74% | -295.60% | -412.19% | -183.23% | -199.83% |
FCF Margin | - | -276.24% | -183.61% | -358.36% | -192.73% | -204.55% |
EBITDA | -114.51 | -113.26 | -117.8 | -127.86 | -80.64 | -58.83 |
EBITDA Margin | -321.32% | -315.08% | -331.04% | -411.17% | -176.13% | -177.23% |
EBIT | -114.51 | -115.22 | -119.61 | -129.53 | -82.13 | -60.45 |
EBIT Margin | -321.32% | -320.53% | -336.14% | -416.56% | -179.39% | -182.10% |
Effective Tax Rate | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.93% |